Daily Respiratory Research Analysis
Analyzed 218 papers and selected 3 impactful papers.
Summary
Analyzed 218 papers and selected 3 impactful articles.
Selected Articles
1. Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
In 322 patients with EGFR-variant nonsquamous NSCLC after EGFR-TKI therapy, ivonescimab plus pemetrexed/carboplatin significantly improved overall survival versus chemotherapy alone (median 16.8 vs 14.1 months; HR 0.74; P=0.02). Thirty-month survival was higher with ivonescimab (29.1% vs 18.4%), with more grade ≥3 adverse events but an acceptable safety profile.
Impact: This double-blind phase 3 trial demonstrates a clinically meaningful OS benefit with a novel bispecific PD-1/VEGF antibody added to standard chemotherapy in a high-need post-TKI population.
Clinical Implications: For EGFR-variant NSCLC progressing after EGFR-TKIs, adding ivonescimab to pemetrexed/carboplatin offers an evidence-based option to improve survival, warranting consideration in treatment algorithms, with careful AE monitoring.
Key Findings
- Ivonescimab plus chemotherapy improved median overall survival to 16.8 months versus 14.1 months (HR 0.74; 95% CI, 0.58-0.95; P=.02).
- Estimated 30-month survival was higher with ivonescimab (29.1% vs 18.4%).
- Grade ≥3 treatment-emergent adverse events occurred more frequently with ivonescimab (67.1% vs 54.7%) but were considered acceptable.
Methodological Strengths
- Randomized, double-blind, placebo-controlled phase 3 design across 55 sites
- Predefined hierarchical testing with independent radiologic review for PFS and mature OS analysis
Limitations
- Conducted exclusively in China, which may limit generalizability across ethnic and healthcare settings
- Higher incidence of grade ≥3 adverse events with ivonescimab requiring vigilant monitoring
Future Directions: Head-to-head comparisons with other post-TKI regimens, biomarker stratification (e.g., PD-L1/VEGF signatures), and global trials to validate efficacy and safety across populations.
IMPORTANCE: Patients with epidermal growth factor receptor (EGFR) gene variant nonsquamous non-small cell lung cancer (NSCLC) who have disease progression after prior EGFR tyrosine kinase inhibitor (TKI) therapy have limited treatment options, creating a need for more effective subsequent therapies. OBJECTIVE: To provide final overall results of a trial assessing whether adding ivonescimab (a bispecific antibody targeting programmed cell death protein 1 and vascular endothelial growth factor) to chemotherapy improves overall survival in this population. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, place...
2. Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial.
In this phase 2 proof-of-concept trial, neoadjuvant retlirafusp alfa demonstrated sustained 3-year EFS and OS in unresectable stage III NSCLC, with particularly favorable outcomes among patients proceeding to surgery after induction. Safety was consistent with prior reports and no new signals emerged with longer follow-up.
Impact: This study advances the neoadjuvant paradigm by using a bifunctional anti–PD-L1/TGF-β agent and shows clinically meaningful long-term outcomes and surgical conversion benefits in stage III NSCLC.
Clinical Implications: For selected unresectable stage III NSCLC without EGFR/ALK alterations, neoadjuvant immunotherapy with a response-adapted plan to pursue surgery where feasible may improve long-term outcomes; multidisciplinary evaluation remains essential.
Key Findings
- Three-year EFS was 50.5% in combination arms (A+B) and 77.1% in the high-PD-L1 monotherapy arm.
- Three-year OS was 68.3% (A+B) and 87.5% (monotherapy arm).
- Patients converted to surgery after induction had higher 3-year EFS/OS (69.5%/84.9%) than those receiving radiotherapy (50.8%/70.4%).
- No new safety signals were observed with extended median follow-up of 39.4 months.
Methodological Strengths
- Prospective phase 2 design with predefined cohorts, including a randomized high–PD-L1 subset.
- Long median follow-up (39.4 months) with clinically relevant endpoints (EFS and OS).
Limitations
- Small sample sizes in the randomized high–PD-L1 arms limit precision and generalizability.
- Predominantly nonrandomized allocation in the larger cohort may introduce selection bias.
Future Directions: Confirmatory randomized trials comparing retlirafusp-based neoadjuvant regimens to standard chemoradiation are needed, with biomarker-driven selection (e.g., PD-L1, TGF-β signatures) and standardized criteria for surgery conversion.
TRAILBLAZER is a proof-of-concept phase 2 study (ClinicalTrials.gov, NCT04580498) of neoadjuvant retlirafusp alfa (an anti-PD-L1/TGF-β bifunctional agent) in unresectable stage III non-small cell lung cancer (NSCLC) not harboring EGFR or ALK alterations. During induction, retlirafusp alfa was administered either with chemotherapy or as monotherapy, followed by surgery or radiotherapy as assessed by a local multidisciplinary team and consolidation retlirafusp alfa. Patients without high PD-L1 expression were allocated to retlirafusp alfa plus chemotherapy (arm A; n = 88); patients with high PD-L1 expression were randomly allocated at a 1:1 ratio to retlirafusp alfa combination (arm B; n = 9) or monotherapy (arm C; n = 10). In this updated analysis (data cutoff, March 24, 2025), the median follow-up was 39.4 months. The event-free survival (EFS) rate at 3 years was 50.5% (95% CI 39.0-61.0) in arm A + B and 77.1% (34.5-93.9) in arm C; the corresponding overall survival (OS) rates at 3 years were 68.3% (95% CI 57.5-77.0) and 87.5% (38.7-98.1), respectively. Among 27 patients who underwent surgery, the 3-year EFS and OS rates were 69.5% (95% CI 48.1-83.5) and 84.9% (64.5-94.0), respectively, versus 50.8% (36.5-63.4) and 70.4% (56.7-80.5), respectively, in radiotherapy-treated patients. The safety data were consistent with those in a previous report. With extended follow-up, the study regimen showed sustained survival benefits with no new safety signals. Patients who underwent surgery after induction treatment achieved clinically meaningful survival gains. Our findings support the use of neoadjuvant immunotherapy with a response-adapted surgical strategy as a promising approach for unresectable stage III NSCLC.
3. Personalized Pathogenic Nanoplastic Coronas Orchestrate Efferocytosis-Driven Immune Evasion in Lung Adenocarcinoma.
Inhaled PET nanoplastics accelerated tumor growth in lung adenocarcinoma-bearing mice. Patient-derived bronchoalveolar lavage fluid formed a lysozyme-enriched corona on nanoplastics that remodeled LYZ conformation and activated TLR4 and a PGRN–LXRα axis, increasing lysosomal acidification-dependent efferocytosis, M2 macrophage polarization, and reducing CD8+ T-cell infiltration.
Impact: This mechanistic study links environmental nanoplastics to tumor immune evasion through a disease-specific protein corona, uncovering a novel TLR4–PGRN–LXRα–efferocytosis pathway in the lung tumor microenvironment.
Clinical Implications: While preclinical, the findings suggest potential targets (TLR4, PGRN–LXRα, efferocytosis) and highlight environmental exposure mitigation as adjunctive strategies in lung cancer care and prevention.
Key Findings
- Inhaled PET nanoplastics accelerated lung adenocarcinoma growth in tumor-bearing mice.
- Patient BALF produced a lysozyme-enriched nanoplastic corona correlated with tumor stage and metastasis.
- Corona-bound LYZ activated TLR4 and a PGRN–LXRα axis, increasing efferocytosis, promoting M2 macrophage polarization, and reducing CD8+ T-cell infiltration.
Methodological Strengths
- Multi-system approach spanning in vivo tumor models and human BALF proteomics
- Mechanistic dissection linking corona composition to defined signaling (TLR4, PGRN–LXRα) and functional immune outcomes
Limitations
- Environmental exposure levels and composition may differ from experimental PET nanoplastics
- Translational relevance requires validation in human cohorts and orthogonal exposure models
Future Directions: Prospective human exposure–omics studies, intervention tests targeting TLR4/PGRN–LXRα/efferocytosis, and regulatory science to mitigate high-risk nontailpipe exposures.
Airborne nanoplastic (NP) pollution is an emerging threat to respiratory health. Although inhaled NPs rapidly acquire a protein corona that shapes their bioactivity, the consequences of this process in cancer-susceptible lungs remain unclear. Here, we investigated whether NPs form a disease-specific pathogenic protein corona in lung adenocarcinoma that rewires immune signaling and accelerates tumor progression. Polyethylene terephthalate (PET) NPs were generated by mechanical fragmentation and extensively characterized. In tumor-bearing mice, inhaled PET NPs accelerated tumor growth relative to controls. Proteomic analysis of PET NPs incubated with bronchoalveolar lavage fluid from patients with lung adenocarcinoma identified lysozyme (LYZ) as a selectively en...